VNX-204

VNX-204 is an investigational AAV-delivered T-cell immuno-gene therapy being developed by Vironexis Biotherapeutics for the treatment of pancreatic cancer. Utilizing the proprietary TransJoin™ platform, VNX-204 employs an adeno-associated virus (AAV) vector to deliver a genetic payload that instructs host cells to produce bispecific T-cell engager proteins in vivo. These proteins are designed to bridge endogenous T cells with specific antigens expressed on pancreatic cancer cells, thereby triggering a targeted cytotoxic immune response against the tumor. This approach aims to provide sustained therapeutic levels of T-cell engagers from a single administration, potentially overcoming the pharmacokinetic limitations of traditional recombinant bispecific antibodies. As of early 2025, the program is in the discovery stage.